D Khanna

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Ayurvedic medicine: it is "time" for scientifically sound studies
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, Los Angeles, CA 90085, USA
    Semin Arthritis Rheum 34:703-4. 2005
  2. ncbi The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study
    Matthew L Mundwiler
    North Suburban Rheumatologists, Des Plaines, IL 60016, USA
    Arthritis Res Ther 11:R94. 2009
  3. ncbi Health-related quality of life--an introduction
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, 1000 Veterans Ave, Rm 32 59 Rehabilitation Bldg, Los Angeles, CA 90095, USA
    Am J Manag Care 13:S218-23. 2007
  4. ncbi Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
    Dinesh Khanna
    University of California, Los Angeles, CA, USA
    Arthritis Rheum 61:1257-63. 2009
  5. ncbi Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial
    Dinesh Khanna
    David Geffen School of Medicine, and School of Public Health, University of California, Los Angeles, USA
    Arthritis Rheum 60:1102-11. 2009
  6. ncbi Development of a provisional core set of response measures for clinical trials of systemic sclerosis
    D Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, California 90095, USA
    Ann Rheum Dis 67:703-9. 2008
  7. ncbi Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trial
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    J Rheumatol 35:466-8. 2008
  8. ncbi A randomized study of scleroderma health state values: a picture is worth a thousand words, and quite a few utiles. [corrected]
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Med Decis Making 29:7-14. 2009
  9. ncbi The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    J Rheumatol 35:2339-43. 2008
  10. ncbi A standardized core set for systemic sclerosis clinical trials. First step in development of combined response index
    D Khanna
    Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 47:v31-2. 2008

Detail Information

Publications91

  1. ncbi Ayurvedic medicine: it is "time" for scientifically sound studies
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, Los Angeles, CA 90085, USA
    Semin Arthritis Rheum 34:703-4. 2005
  2. ncbi The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study
    Matthew L Mundwiler
    North Suburban Rheumatologists, Des Plaines, IL 60016, USA
    Arthritis Res Ther 11:R94. 2009
    ..Similar analyses were performed for bone marrow edema, predicting a subsequent MRI erosion. Descriptive results of other lesions are reported...
  3. ncbi Health-related quality of life--an introduction
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, 1000 Veterans Ave, Rm 32 59 Rehabilitation Bldg, Los Angeles, CA 90095, USA
    Am J Manag Care 13:S218-23. 2007
    ....
  4. ncbi Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
    Dinesh Khanna
    University of California, Los Angeles, CA, USA
    Arthritis Rheum 61:1257-63. 2009
    ..To refine the previously developed scleroderma (systemic sclerosis [SSc]) gastrointestinal tract (GIT) instrument (SSC-GIT 1.0)...
  5. ncbi Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial
    Dinesh Khanna
    David Geffen School of Medicine, and School of Public Health, University of California, Los Angeles, USA
    Arthritis Rheum 60:1102-11. 2009
    ....
  6. ncbi Development of a provisional core set of response measures for clinical trials of systemic sclerosis
    D Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, California 90095, USA
    Ann Rheum Dis 67:703-9. 2008
    ..To develop a provisional core set of response measures for clinical trials of systemic sclerosis (SSc)...
  7. ncbi Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trial
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    J Rheumatol 35:466-8. 2008
    ..We assessed if HAQ-DI scores are different when calculated with and without aids/devices, and if apparent responsiveness changes when scored in these 2 ways...
  8. ncbi A randomized study of scleroderma health state values: a picture is worth a thousand words, and quite a few utiles. [corrected]
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Med Decis Making 29:7-14. 2009
    ..We assess utilities from the general public for health states common in scleroderma (SSc) by describing the health states in writing alone v. with photographs of patients with SSc...
  9. ncbi The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    J Rheumatol 35:2339-43. 2008
    ..To estimate the minimally important difference (MID) for a fatigue visual analog scale (VAS) using patient-reported anchors (fatigue, pain, and overall health)...
  10. ncbi A standardized core set for systemic sclerosis clinical trials. First step in development of combined response index
    D Khanna
    Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 47:v31-2. 2008
    ..The Delphi exercise identified 11 domains relevant to SSc clinical trials. Currently, efforts are under way to develop a combined response index for clinical trials in diffuse cutaneous SSc...
  11. ncbi The disutility of chronic gout
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, 1000 Veteran Avenue, Los Angeles, CA 90095, USA
    Qual Life Res 17:815-22. 2008
    ..Gout is a chronic painful inflammatory arthritis. Data regarding the impact of gout on health-related quality of life, however, are limited...
  12. ncbi Oral cyclophosphamide for active scleroderma lung disease: a decision analysis
    Dinesh Khanna
    Division of Rheumatology, School of Public Health, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Med Decis Making 28:926-37. 2008
    ..Also, the long-term balance of risk and benefit remains unclear...
  13. ncbi Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study
    Dinesh Khanna
    Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 48:1537-40. 2009
    ..Our objective was to assess minimally important difference (MID) for Mahler's Transition Dyspnoea Index (TDI) in SLS...
  14. ncbi Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases
    Dinesh Khanna
    David Geffen School of Medicine at UCLA, 1000 Veteran Avenue, Room 32 59 Rehabilitation Building, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 49:1184-8. 2010
    ..EF is a rare fibrosing disorder that may involve skin and internal organs. Current therapies include moderate- to high-dose glucocorticoids with or without use of immunosuppressives...
  15. ncbi Minimally important differences of the gout impact scale in a randomized controlled trial
    Dinesh Khanna
    Department of Medicine, Division of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, University of California at San Diego, La Jolla, CA 90095, USA
    Rheumatology (Oxford) 50:1331-6. 2011
    ..Our objective was to assess minimally important differences (MIDs) for the GIS administered in a randomized controlled trial (RCT) assessing rilonacept vs placebo for prevention of gout flares during initiation of allopurinol therapy...
  16. ncbi Quality indicator set for systemic sclerosis
    Dinesh Khanna
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA
    Clin Exp Rheumatol 29:S33-9. 2011
    ..Our objective was to develop QIs for patients with SSc...
  17. ncbi Health-related quality of life in adults reporting arthritis: analysis from the National Health Measurement Study
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, 1000 Veteran Avenue, Rm 32 59 Rehabilitation Building, Los Angeles, CA 90095, USA
    Qual Life Res 20:1131-40. 2011
    ..Arthritis is the leading cause of disability in the United States. We assess the generic health-related quality-of-life (HRQOL) among a nationally representative sample of U.S. adults with and without self-reported arthritis...
  18. ncbi Willingness to pay for a cure in patients with chronic gout
    Dinesh Khanna
    Division of Immunology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Med Decis Making 28:606-13. 2008
    ..Gout is a chronic painful inflammatory arthritis. The authors interviewed patients with chronic stable gout to assess their hypothetical willingness to pay (WTP) to be cured of their gout. Patients and..
  19. ncbi Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Clin Exp Rheumatol 28:S55-62. 2010
    ..Recent investigations into the pathogenesis of SSc-ILD have led to a renewed interest in assessing targeted therapies in SSc-ILD. With this in mind, we propose recommendations for the design of future SSc-ILD studies in this review...
  20. ncbi Evidence-based management of rapidly progressing systemic sclerosis
    Dinesh Khanna
    UCLA Scleroderma Program, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Best Pract Res Clin Rheumatol 24:387-400. 2010
    ..Some of the recent clinical trials are reviewed and discussed in detail...
  21. ncbi Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial
    Puja P Khanna
    Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 49:955-9. 2010
    ....
  22. ncbi Differences in presentation of younger and older systemic sclerosis patients in clinical trials
    H H Weng
    Amgen Inc, Thousand Oaks, CA, USA
    Clin Exp Rheumatol 28:S10-4. 2010
    ..To compare the characteristics of younger and older subjects with diffuse cutaneous systemic sclerosis (SSc) entering clinical trials...
  23. ncbi Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study
    Jonathan Goldin
    Department of Radiologic Sciences, David Geffen School of Medicine, School of Public Health, University of California Los Angeles, Los Angeles, CA 90095, USA
    Chest 136:1333-40. 2009
    ..This study examined thoracic high-resolution CT (HRCT) scans obtained during the SLS for treatment-associated changes over time...
  24. ncbi Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials
    Sogol Amjadi
    Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Arthritis Rheum 60:2490-8. 2009
    ....
  25. ncbi Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study
    Dinesh Khanna
    David Geffen School of Medicine, University of California, Los Angeles, USA
    Arthritis Rheum 52:592-600. 2005
    ....
  26. ncbi Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study
    Dinesh Khanna
    University of Cincinnati, Cincinnati, Ohio 45267 0563, USA
    Arthritis Rheum 56:1676-84. 2007
    ..To assess the impact of cyclophosphamide (CYC) on the health-related quality of life (HRQOL) of patients with scleroderma after 12 months of treatment...
  27. ncbi Health values of patients with systemic sclerosis
    Dinesh Khanna
    University of Cincinnati Medical Center, Institute for the Study of Health, University of Cincinnati, and Veterans Affairs Medical Center, Cincinnati, Ohio, USA
    Arthritis Rheum 57:86-93. 2007
    ..To assess health values in subjects with systemic sclerosis (SSc) and determine variability explained by demographics, clinical factors, health status, and disease severity...
  28. ncbi Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)
    Dinesh Khanna
    David Geffen School at University of California, Los Angeles, CA, USA
    J Rheumatol 36:2356-61. 2009
    ..CRISS and EPOSS are being developed through the OMERACT process. Through Delphi process and literature review significant progress has been made for both indices, and prospective data are being collected...
  29. ncbi ACR remission criteria and response criteria
    V K Ranganath
    Division of Rheumatology, Department of Medicine, University of California, Los Angeles, California 90095 1670, USA
    Clin Exp Rheumatol 24:S-14-21. 2006
    ..Nevertheless, rheumatologists yearn for the eradication of inflammation in all RA patients, and attaining remission may be achievable in the future...
  30. ncbi Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases
    V Strand
    Division of Immunology Rheumatology, Stanford University School of Medicine, Stanford, California, USA
    Ann Rheum Dis 68:1800-4. 2009
    ....
  31. ncbi Systemic sclerosis and bilateral lung transplantation: a single centre experience
    R Saggar
    Division of Pulmonary and Critical Care Medicine, Dept of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1690, USA
    Eur Respir J 36:893-900. 2010
    ..AR rates may be significantly higher in the SSc group. Longer follow-up is necessary to determine the effects of gastrointestinal dysfunction and AR on late allograft function in SSc LTR...
  32. ncbi Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort
    Veena K Ranganath
    UCLA, Department of Medicine, Division of Rheumatology, Rehabilitation Center, Room 32 59, 1000 Veteran Avenue, Los Angeles, CA 90095 1670, USA
    Ann Rheum Dis 66:1633-40. 2007
    ....
  33. ncbi The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials
    Janet E Pope
    Division of Rheumatology, Department of Medicine, University of Western Ontario, London, Canada
    J Rheumatol 36:254-9. 2009
    ....
  34. ncbi Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials
    Karen Au
    Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Curr Rheumatol Rep 11:111-9. 2009
    ..A randomized double-blind controlled trial by the Scleroderma Lung Study Research Group is currently comparing the efficacy and safety of mycophenolate mofetil versus oral cyclophosphamide...
  35. ncbi Validating and assessing the sensitivity of the Health Assessment Questionnaire-Disability Index-derived Short Form-6D in patients with early aggressive rheumatoid arthritis
    Sogol S Amjadi
    Division of Rheumatology, University of California Los Angeles School of Medicine, Department of Health Services, 1000 Veteran Avenue, Room 32 59, Rehabilitation Center, Los Angeles, CA 90095, USA
    J Rheumatol 36:1150-7. 2009
    ..We evaluated the construct validity of the HAQ-DI-derived Short Form-6D (SF-6D) score and assessed its responsiveness to change over 6- and 12-month followup periods in patients with early aggressive rheumatoid arthritis (RA)...
  36. ncbi Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis
    Haoling H Weng
    Amgen Inc, Thousand Oaks, California, USA
    J Rheumatol 37:550-7. 2010
    ..To evaluate responses by time to initiation of nonbiologic disease-modifying antirheumatic drugs (DMARD) in a DMARD-naive cohort of patients with early seropositive rheumatoid arthritis (RA)...
  37. ncbi Outcome evaluations in gout
    H Ralph Schumacher
    Division of Rheumatology, University of Pennsylvania School of Medicine, and Veterans Affairs Medical Center, Philadelphia, Pennsylvania 19104, USA
    J Rheumatol 34:1381-5. 2007
    ..Final validation of these outcomes has not yet been achieved. In summary, the unique problems of evaluating outcomes in gout are finally being addressed. While no measures are available for use yet, an agenda has been developed...
  38. ncbi Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study
    D Khanna
    Division of Immunology, Department of Medicine, University of Cincinnati, ML 0563, Cincinnati, OH 45267 0563, USA
    Ann Rheum Dis 65:1325-9. 2006
    ..To estimate minimally important differences (MIDs) in scores for the modified Rodnan Skin Score (mRSS) and Health Assessment Questionnaire-Disability Index (HAQ-DI) in a clinical trial on diffuse systemic sclerosis (SSc)...
  39. ncbi Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis
    Dinesh Khanna
    Division of Immunology, Department of Internal Medicine, University of Cincinnati Medical Center, PO Box 670563, Cincinnati, OH 45267 0563, USA
    Qual Life Res 16:1083-92. 2007
    ....
  40. ncbi Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities
    Rajeev Saggar
    David Geffen School of Medicine at University of California, Los Angeles, CA 90095 1690, USA
    Arthritis Rheum 62:3741-50. 2010
    ..We undertook this study to describe the hemodynamic response to exercise in a homogeneous population of patients with scleroderma spectrum disorders at risk of developing pulmonary vascular disease...
  41. ncbi High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease
    Jonathan G Goldin
    David Geffen School of Medicine at UCLA, Department of Radiology, Los Angeles, CA 90095 1721, USA
    Chest 134:358-67. 2008
    ..The frequency, nature, and progression of interstitial lung disease seen on high-resolution CT (HRCT) scans in patients with diffuse SSc (dcSSc) compared with those with limited SSc (lcSSc) has not been well characterized...
  42. ncbi Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study
    Tien I Karleen Su
    University of Southern California, Los Angeles, CA 90095 1670, USA
    Arthritis Rheum 60:3821-30. 2009
    ..To assess the safety and efficacy of rapamycin in the treatment of diffuse systemic sclerosis (SSc; scleroderma)...
  43. ncbi Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database
    Veena K Ranganath
    Department of Medicine, Division of Rheumatology, UCLA Rehabilitation Center, University of California, Los Angeles, California 90095 1670, USA
    J Rheumatol 35:1966-71. 2008
    ....
  44. ncbi Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?
    Dinesh Khanna
    University of California, Los Angeles 90095, USA
    Arthritis Rheum 50:1040-50. 2004
  45. ncbi Association of tumor necrosis factor alpha polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort
    Dinesh Khanna
    David Geffen School of Medicine at the University of California, Los Angeles, and the Veterans Affairs Medical Center, Cincinnati, Ohio 45267 0563, USA
    Arthritis Rheum 54:1105-16. 2006
    ..To determine whether the tumor necrosis factor alpha (TNFA) -308 guanine-to-adenosine polymorphism and/or the shared epitope (SE) is associated with radiographic damage in patients with early rheumatoid arthritis (RA)...
  46. ncbi Interaction between RANKL and HLA-DRB1 genotypes may contribute to younger age at onset of seropositive rheumatoid arthritis in an inception cohort
    Hui Wu
    University of California, Los Angeles90095 1670, USA
    Arthritis Rheum 50:3093-103. 2004
    ..To determine whether the RANKL and HLA-DRB1 "shared epitope" (SE) genotypes contribute to the development of rheumatoid arthritis (RA)...
  47. ncbi Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials
    Marian Kaldas
    UCLA Olive View, Sylmar, CA, USA
    Rheumatology (Oxford) 48:1143-6. 2009
    ..Our objective was to evaluate the sensitivity of change over time of individual body sites used in the calculation of total MRSS...
  48. ncbi Scleroderma--developing measures of response
    Daniel E Furst
    University of California at Los Angeles, CA 90025, USA
    J Rheumatol 32:2477-80. 2005
    ..Deliberations focused on progress in the assessment of gastrointestinal disease, renal physiology, vascular damage, and the unique challenges inherent in studying pediatric patients with scleroderma...
  49. ncbi Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands, but not with more rapid progression of damage
    Dinesh Khanna
    University of California at Los Angeles, USA
    Arthritis Rheum 52:2284-92. 2005
    ..To investigate the impact of patient age at symptom onset on radiographic joint damage at study entry, and on subsequent progression of damage in a cohort of patients with early seropositive rheumatoid arthritis (RA)...
  50. ncbi Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, Los Angeles, California, USA
    J Rheumatol 32:832-40. 2005
    ....
  51. ncbi Etanercept ameliorates sarcoidosis arthritis and skin disease
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, UCLA Center for the Health Sciences, Los Angeles, California, USA
    J Rheumatol 30:1864-7. 2003
    ..We discuss the possible mechanisms of action of anti-TNF agents in granulomatous diseases and suggest that chronic, resistant sarcoidosis requires combination immunosuppressive therapy...
  52. ncbi Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout
    Puja P Khanna
    Department of Medicine, David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 50:740-5. 2011
    ..Short Form-36 (SF-36) is a validated outcome measure to assess health-related quality of life (HRQOL) in patients with gout. We assessed responsiveness to change of SF-36 in patients with gout...
  53. ncbi Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort
    Dinesh Khanna
    Division of Immunology, Department of Medicine, University of Cincinnati and the Veterans Affairs Medical Center, Cincinnati, Ohio 45267 0563, USA
    Arthritis Rheum 57:440-7. 2007
    ..To evaluate published proposed definitions of minimal disease activity (MDA) and remission in patients with early rheumatoid arthritis (RA)...
  54. ncbi Stress activation of cellular markers of inflammation in rheumatoid arthritis: protective effects of tumor necrosis factor alpha antagonists
    Sarosh J Motivala
    UCLA Semel Institute for Neuroscience and Human Behavior, Cousins Center for Psychoneuroimmunology, University of California, Los Angeles 90095 7076, USA
    Arthritis Rheum 58:376-83. 2008
    ..The purpose of this study was to determine whether RA patients show increased monocyte production of TNFalpha following acute psychological stress and whether such responses are abrogated in RA patients taking TNFalpha antagonists...
  55. ncbi Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument
    Dinesh Khanna
    University of Cincinnati, The Veterans Affairs Medical Center, Cincinnati, Ohio, USA
    Arthritis Rheum 57:1280-6. 2007
    ..Gastrointestinal tract (GIT) involvement occurs in approximately 90% of patients with systemic sclerosis (SSc) and has a major impact on health-related quality of life (HRQOL). We developed an HRQOL instrument for persons with SSc...
  56. ncbi Classifying radiographic progression status in early rheumatoid arthritis patients using propensity scores to adjust for baseline differences
    Grace S Park
    Department of Biostatistics, School of Public Health, University of California, Los Angeles, CA 90095 1772, USA
    Stat Methods Med Res 16:13-29. 2007
    ..However, after propensity score adjustment for baseline differences, we noticed nonsignificant (P > 0.05) nonprogression in patients given earlier treatment. We conclude that propensity score analysis reduced but did not remove all bias...
  57. ncbi Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study
    Daniel E Furst
    Division of Rheumatology, Department of Medicine, University of California Los Angeles, CA 90095 1670, USA
    Ann Rheum Dis 66:893-9. 2007
    ..To incorporate a new trial design to examine clinical response, cytokine expression and joint imaging in patients with rheumatoid arthritis (RA) switching from etanercept to infliximab treatment...
  58. ncbi Systemic sclerosis - continuing progress in developing clinical measures of response
    Daniel Furst
    University of California at Los Angeles, Los Angeles, California 90025, USA
    J Rheumatol 34:1194-200. 2007
    ..Another Delphi exercise is designed to develop consensus regarding a combined SSc response index to be validated in future RCT...
  59. ncbi Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease
    Donald P Tashkin
    Department of Medicine, David Geffen School of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1690, USA
    Am J Respir Crit Care Med 176:1026-34. 2007
    ..Although treatment-related benefits in pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1 year of therapy, the duration of benefit beyond 1 year was unclear...
  60. ncbi Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study
    Christina Charles-Schoeman
    Division of Rheumatology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, California 90095 1670, USA
    J Rheumatol 34:1459-64. 2007
    ..We examined the effects of atorvastatin 80 mg daily on the inflammatory properties of HDL and clinical disease activity in RA...
  61. ncbi Use of a medication control officer to reduce bias in a clinical trial: lessons learned from the scleroderma lung study
    Vivien M Hsu
    Division of Rheumatology, UMDNJ Scleroderma Program, New Brunswick, NJ 08903, USA
    Clin Trials 7:85-9. 2010
    ....
  62. ncbi Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique
    Raymond S Douglas
    Department of Ophthalmology, Jules Stein Eye Institute and David Geffen School of Medicine at University of California, Los Angeles, CA 90095, USA
    Arch Ophthalmol 127:1155-60. 2009
    ..To identify components of a provisional clinical response index for thyroid eye disease using a modified Delphi technique...
  63. ncbi Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients
    Veena K Ranganath
    Division of Rheumatology, Department of Biostatistics and School of Public Health, Geffen School of Medicine at UCLA, Los Angeles, California 90095-1670, USA
    J Rheumatol 32:1040-2. 2005
    ..CONCLUSION: In patients with late-onset and younger-onset RA with similar disease duration and severity, the apparent discrepancy in elevation of both the baseline ESR and CRP disappears after age-adjustment...
  64. ncbi Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration
    Mansoor Ahmed
    Division of Immunology, Department of Medicine, University of Cincinnati Medical Center, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    J Rheumatol 33:2344-6. 2006
    ..The patient had recurrence of neurological symptoms upon repeated administration of adalimumab, and resolution of symptoms after withdrawal...
  65. ncbi The impact of rheumatoid arthritis and treatment on patients' lives
    Vibeke Strand
    Division of Immunology Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA
    Clin Exp Rheumatol 28:S32-40. 2010
    ..These extend the more traditional measures of efficacy into outcomes that are more central to patients' daily lives...
  66. ncbi Perceptions of disease and health-related quality of life among patients with gout
    Susan J Lee
    San Diego Veterans Affairs Medical Center, San Diego, CA, USA
    Rheumatology (Oxford) 48:582-6. 2009
    ..To assess the impact of gout on health-related quality of life (HRQoL) among patients in three large US cities...
  67. ncbi Validation of single-factor structure and scoring protocol for the Health Assessment Questionnaire-Disability Index
    Jason C Cole
    University of California, Los Angeles, CA, USA
    Arthritis Rheum 53:536-42. 2005
    ..In addition, the findings suggest some benefit from a secondary interpretation of the scores based on domains that measure motor skills...
  68. ncbi Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies
    Dinesh Khanna
    Division of Immunology, Department of Medicine, University of Cincinnati and Veterans Affairs Medical Center, Cincinnati, Ohio 45267 0563, USA
    Arthritis Rheum 52:3030-8. 2005
    ..To examine the effect of folic acid on the efficacy of methotrexate (MTX) treatment in rheumatoid arthritis (RA) at 12 months in 2 phase III randomized controlled trials (RCTs) of leflunomide in which MTX was used as a comparator...
  69. ncbi Intravenous drug abuse mimicking vasculitis
    D Khanna
    Department of Internal Medicine, Wright State University, Dayton, Ohio, USA
    South Med J 94:505-7. 2001
    ..We report a case of intravenous drug abuse manifesting with signs and symptoms suggestive of vasculitis. This case highlights the need for diagnostic precision in the evaluation of suspected vasculitis...
  70. ncbi Safety of tumour necrosis factor-alpha antagonists
    Dinesh Khanna
    Division of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Drug Saf 27:307-24. 2004
    ..At present there is no evidence implicating TNFalpha antagonists with embryotoxicity, teratogenicity or increased pregnancy loss...
  71. ncbi Pregnancy outcomes in systemic sclerosis, primary pulmonary hypertension, and sickle cell disease
    Eliza F Chakravarty
    Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA
    Obstet Gynecol 111:927-34. 2008
    ..We estimated the nationwide occurrence of pregnancies in women with these conditions and compared pregnancy outcomes to the general obstetric population...
  72. ncbi A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls
    Vandana Khurma
    University of Cincinnati, Cincinnati, Ohio, USA
    Arthritis Rheum 59:591-7. 2008
    ..The objective of the pilot study was to determine 1) the prevalence of subclinical coronary atherosclerosis in SSc and 2) serum piHDL levels as a potential novel marker of atherosclerotic risk in SSc...
  73. ncbi Angiocentric T cell lymphoma of the central nervous system in a patient with Sjögren's syndrome
    Dinesh Khanna
    Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095-1670, USA
    J Rheumatol 29:1548-50. 2002
    ..We describe a young Caucasian woman with a 7 year history of SS, who presented with meningeal signs and symptoms and was found to have non-Hodgkin's lymphoma of the central nervous system...
  74. ncbi Hemopoietic stem cell transplantation in rheumatic diseases--an update
    Paige de Buys
    Division of Immunology, Department of Medicine, University of Cincinnati, Cincinnati, OH, United States
    Autoimmun Rev 4:442-9. 2005
    ..Transplant in SSc patients has offered durable responses with improving transplant-related mortality related to careful patient selection...
  75. ncbi Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study
    Tracy Frech
    Department of Internal Medicine, Division of Rheumatology, University of Utah, Salt Lake City, UT, USA
    Rheumatology (Oxford) 50:1280-7. 2011
    ..Rheumatologic disorders are associated with sleep disturbances. This study examines sleep disturbance correlates in patients with SSc...
  76. ncbi Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis
    Vijay Bodukam
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 50:330-4. 2011
    ..0 instrument; and (ii) to explore which GI-specific symptom scales are associated with depressed mood in patients with SSc...
  77. ncbi The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial
    Puja P Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Ann Rheum Dis 69:588-91. 2010
    ..The Raynaud's condition score (RCS) is a validated outcome measure for Raynaud's phenomenon (RP)...
  78. ncbi Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients
    Jason C Cole
    Consulting Measurement Group, Huntington Beach, CA 91403, USA
    Qual Life Res 15:1383-94. 2006
    ..The goal of the current study was to examine the structural validity of the HAQ-DI in patients with systemic sclerosis (SSc, scleroderma) and to compare its performance with that in patients with RA...
  79. ncbi Acute injection site reaction to intraarticular etanercept administration
    Erin L Arnold
    Arthritis Rheum 48:2078-9. 2003
  80. ncbi Patient self-administered joint tenderness counts in rheumatoid arthritis are reliable and responsive to changes in disease activity
    Fernando Figueroa
    Department of Medicine, Universidad de Los Andes, Santiago de Chile, Chile
    J Rheumatol 34:54-6. 2007
    ..To examine whether self-assessment of tender and swollen joints by patients with rheumatoid arthritis (RA) can be used to evaluate changes in disease activity instead of joint counts by physicians...
  81. ncbi Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis
    Oliver Distler
    University Hospital Zurich, Zurich, Switzerland
    Arthritis Rheum 59:867-75. 2008
    ..The aim of the present study was to establish an expert consensus regarding which outcome measures are most appropriate for clinical trials in PAH-SSc...
  82. ncbi Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192
    Christopher P Denton
    Royal Free Hospital, London, UK
    Arthritis Rheum 56:323-33. 2007
    ..To evaluate CAT-192, a recombinant human antibody that neutralizes transforming growth factor beta1 (TGFbeta1), in the treatment of early-stage diffuse cutaneous systemic sclerosis (dcSSc)...
  83. ncbi Health-related quality of life in rheumatoid arthritis
    Daniel E Furst
    Am J Manag Care 14:234. 2008
  84. ncbi Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial
    Peter A Merkel
    Boston University School of Medicine, Boston, MA 02118, USA
    Arthritis Rheum 59:699-705. 2008
    ..To determine the validity, reliability, and feasibility of durometer measurements of skin hardness as an outcome measure in clinical trials of scleroderma...
  85. ncbi Outcome measures in systemic sclerosis: an update on instruments and current research
    Dinesh Khanna
    Division of Immunology, Department of Internal Medicine, University of Cincinnati, PO Box 670563, Cincinnati, OH 45267 0563, USA
    Curr Rheumatol Rep 9:151-7. 2007
    ..This review provides an update on currently used outcome measures in SSc with specific attention on newer tools and also describes methodology under development...
  86. ncbi American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
    Kenneth G Saag
    University of Alabama, Birmingham, AL, USA
    Arthritis Rheum 59:762-84. 2008
  87. ncbi Cyclooxygenase 2 controversy: thoughts on the process of discovery, development, and assessment of benefit and risk of therapies for chronic immunoinflammatory diseases of uncertain autoimmune etiology
    Daniel E Furst
    Arthritis Rheum 55:683-6. 2006
  88. ncbi Meloxicam in rheumatoid arthritis
    Mansoor Ahmed
    David Geffen School of Medicine, Los Angeles, CA, USA
    Expert Opin Drug Metab Toxicol 1:739-51. 2005
    ..Clinical trials have shown that meloxicam at 7.5 - 15 mg/day is as effective as diclofenac, piroxicam and naproxen as an anti-inflammatory and analgesic, and was associated with fewer GI adverse effects...
  89. ncbi Measuring process of arthritis care: the Arthritis Foundation's quality indicator set for rheumatoid arthritis
    Dinesh Khanna
    Division of Immunology, University of Cincinnati and VAMC, OH, USA
    Semin Arthritis Rheum 35:211-37. 2006
    ....
  90. ncbi COX-2 controversy: where are we and where do we go from here?
    Dinesh Khanna
    Division of Immunology, Department of Medicine, University of Cincinnati, Cincinnati, OH, USA
    Inflammopharmacology 13:395-402. 2005
    ..We give suggestions on the use of coxibs and briefly mention a general approach to the future of coxibs...
  91. ncbi Dating the "window of therapeutic opportunity" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset
    Sogol Amjadi-Begvand
    Division of Rheumatology, UCLA School of Medicine, Los Angeles, California, USA
    J Rheumatol 31:1686-92. 2004
    ..This should be taken into consideration when enrolling patients, when interpreting the findings of early RA clinical trials, and when attempting to ascertain the presence of a window of therapeutic opportunity...